4:["$","div",null,{"className":"min-h-screen bg-white flex flex-col","children":[["$","div",null,{"className":"px-6 pt-6 pb-4 border-b border-gray-100","children":[["$","div",null,{"className":"flex items-center gap-1.5 text-xs text-gray-400 mb-4","children":[["$","a",null,{"href":"/","className":"hover:text-[#26a69a] transition-colors","children":"Market"}],["$","span",null,{"children":"›"}],["$","span",null,{"className":"text-gray-600","children":"PNU-22394"}]]}],["$","div",null,{"className":"text-[10px] text-gray-400 uppercase tracking-widest mb-1","children":"Company Profile"}],["$","h1",null,{"className":"text-2xl font-bold text-gray-900","children":"PNU-22394"}],null]}],["$","div",null,{"className":"flex-1 px-6 py-6","children":[["$","p",null,{"className":"text-sm text-gray-600 leading-relaxed mb-8","children":"PNU-22394, or PNU-22394A, also known as U-22394A, as well as 6-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole, is a serotonin 5-HT2 receptor agonist of the ibogalog family which was studied as an appetite suppressant and antipsychotic but was never marketed. As an ibogalog, PNU-22394 is a cyclized tryptamine and a simplified ibogaine analogue."}],["$","div",null,{"className":"columns-1 md:columns-2 gap-10","children":[["$","div","0",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"Pharmacology"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"PNU-22394 acts as a potent modulator of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. PNU-22394 produces anorectic effects and weight loss in both animals and humans as well as pro-cognitive-like effects in animals. The anorectic effects of PNU-22394 in animals can be blocked by the selective serotonin 5-HT2C receptor antagonist SB-242084. ==History=="}}]]}],["$","div","1",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"History"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"PNU-22394 was first described in the scientific literature by 1967. It was originally evaluated by Upjohn in people with schizophrenia in the 1960s. It showed no antipsychotic effects, but did unexpectedly produce weight loss in most of the patients. Subsequently, in the 2000s, PNU-22394 was studied as an appetite suppressant and weight loss medication. ==Analogues=="}}]]}],["$","div","2",{"className":"mb-8 break-inside-avoid","children":[["$","div",null,{"className":"text-xs font-semibold text-gray-400 uppercase tracking-wide mb-3 border-b border-gray-100 pb-1","children":"Analogues"}],["$","div",null,{"className":"text-sm text-gray-600 leading-relaxed wiki-content","dangerouslySetInnerHTML":{"__html":"Various analogues of PNU-22394 have also been studied and described. ==See also=="}}]]}]]}],"$Lf"]}],"$L10"]}]